TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8642959
Drug: Introduction of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Introduction of artemisinin derivatives in routine treatment
Study: 22917822
Drug: Landiolol hydrochloride
Normalized name: Landiolol Hydrochloride
DrugBank: Landiolol (DB12212)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Landiolol hydrochloride (1 μg/kg per minute after cardiopulmonary bypass or after distal anastomoses)
Study: 9364700
Drug: Separate administration
Normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate administration of DTPa and HBV vaccines
Study: 10495460
Drug: Deferred zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Deferred zidovudine treatment
Study: 24834504
Drug: SRP +
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SRP + MTZ (400 mg TID)
Study: 17560876
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin plus planned glycoprotein IIb/IIIa inhibitor
Study: 10051803
Drug: Magnesium supplementation
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium supplementation (360 mg Mg/day)
Study: 31626835
Drug: Group treatment
Normalized name: Allergenic Extracts Intradermal Kit [9 SO. GRASS GROUP TREATMENT SET]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group treatment program focused on parenting skills (10 weekly sessions)
Study: 11282170
Drug: 6-methylprednisolone therapy
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6-methylprednisolone therapy
Study: 25527661
Drug: Protein intake
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein intake ranging from 0.22 to 2.56 g · kg(‐1) · d(‐1) during early gestation.
Study: 29699852
Drug: SC injection
Normalized name: SC 41930
DrugBank: SC 41930 (DB17101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC injection
Study: 7259512
Drug: Intravenous calcium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous calcium chloride (5 mg/kg intermittent IV bolus)
Study: 31726894
Drug: Intratumoral injection
Normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intratumoral injection of DNX-2401 without tumor resection
Study: 29167980
Drug: Percutaneous platelet
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous platelet concentrate (PC) injection
Study: 7587851
Drug: Multiple insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multiple insulin injection therapy (MIT)
Study: 15982350
Drug: One dose
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One dose of influenza vaccine
Study: 16785774
Drug: High-intensity light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity light treatment
Study: 17301956
Drug: Intravenous carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous carboplatin
Study: 111886
Drug: Low-dose continuous
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose continuous intravenous insulin infusion
Study: 21419776
Drug: Revaccination of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Revaccination of horses with low antibody levels
Study: 8299786
Drug: 0.05 mg
Normalized name: biotin 0.05 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mg transdermal 17 beta‐E2
Study: 21570487
Drug: Exercise combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise combined with vitamin D and calcium supplements
Study: 6262702
Drug: Tiapride infusion
Normalized name: tiapride
DrugBank: Tiapride (DB13025)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiapride infusion
Study: 26613214
Drug: Early prophylactic
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early prophylactic INSURE with surfactant administration immediately after birth
Study: 27801404
Drug: Biological feedback
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological feedback (BFB) technique
Study: 20811658
Drug: 21 mg
Normalized name: aspirin 421 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 21 mg NRT
Study: 20811658
Drug: 42 mg
Normalized name: lithium 42 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 42 mg NRT
Study: 15844708
Drug: Peginterferon alpha-2a
Normalized name: PEGINTERFERON ALPHA-2A 180MCG/ML INJ,1ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peginterferon alpha-2a plus ribavirin (180 microg peg‐interferon alpha‐2a + 800-1000 mg/day ribavirin)
Study: 26985045
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with saline infusion
Study: 8644661
Drug: Enalapril and
Normalized name: enalapril and diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril and loop diuretics with or without digoxin
Study: 8522052
Drug: Cyclosporin A
Normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin A (initial dose of 7.2 +/- 0.1 mg.kg-1.day-1, decreased stepwise and interrupted after 6-62 months)
Study: 7556743
Drug: Tropicamide Novel
Normalized name: Tropicamide
DrugBank: Tropicamide (DB00809)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tropicamide Novel Ophthalmic Delivery System (NODS) and guttae phenylephrine 10% applied once, 2 hours before surgery
Study: 8678384
Drug: Zinc gluconate
Normalized name: Zinc Gluconate
DrugBank: Zinc gluconate (DB11248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zinc gluconate lozenges
Study: 22302316
Drug: Intra-articular betamethasone
Normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-articular betamethasone injections
Study: 28039583
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g D-chiro-inositol plus 400 mcg folic acid once daily
Study: 2882772
Drug: Buccal nitroglycerine
Normalized name: nitroglycerin Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal nitroglycerine (10 mg)
Study: 2882772
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of celiprolol and nitroglycerine
Study: 23272985
Drug: Depression treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depression treatment (received by 168 patients)
Study: 3609190
Drug: Lower tar
Normalized name: Coal Tar
DrugBank: Coal tar (DB11082)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower tar cigarette (10 mg tar, 1.4 mg nicotine)
Study: 792359
Drug: Amikacin plus
Normalized name: Amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Amikacin plus penicillin G (Amik-Pen)
Study: 792359
Drug: Combined antibiotics
Normalized name: combinations of different antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined antibiotics without demonstrated synergy in vitro
Study: 9200048
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser and deep friction massage twice a week for 3 weeks
Study: 23313654
Drug: Inactivated influenza
Normalized name: influenza, inactivated, whole virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated influenza vaccine then Tdap-IPV 28‐35 days later (Group 2)
Study: 16088297
Drug: Balsamodendron mukul
Normalized name: COMMIPHORA MUKUL (GUGGUL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balsamodendron mukul (1.5 g/d)
Study: 151476
Drug: Control infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control infusion with saline
Study: 31571243
Drug: Immediate periodontal
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate periodontal therapy (test group, n=46)
Study: 7746398
Drug: Neutral drug
Normalized name: DentiCare Neutral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutral drug group (n = 59)
Study: 30029204
Drug: Interactive Metronome
Normalized name: Menin-mll interaction inhibitor ko 539
DrugBank: Ziftomenib (DB17171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interactive Metronome (IM) training, 35-40 min per session, twice a week for 6 weeks
Study: 24144243
Drug: Bright light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright light and melatonin capsules
Study: 17519150
Drug: Extended oral
Normalized name: Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended oral contraceptive regimen containing 3 mg drosperinone and 30 microg ethinyl estradiol
Study: 16860046
Drug: 3-day hormone-free
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-day hormone-free interval (HFI)
Study: 16342193
Drug: Granulocyte colony
Normalized name: Granulocyte colony stimulating factor
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Granulocyte colony stimulating factor (G‐CSF, 5 microg/kg/day) administered subcutaneously for 5 days for mobilization of CD34(+) cells.
Study: 23596262
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of praziquantel (40 mg/kg body weight)
Study: 15173537
Drug: Nasal continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal continuous positive airway pressure (NCPAP) after surfactant administration (SURF‐NCPAP group)
Study: 28831951
Drug: Milk protein
Normalized name: Milk protein
DrugBank: Casein (DB10516)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk protein concentrate (PRO, 4×20 g on exercise day and 20 g/d for the following 8 days)
Study: 25948101
Drug: Dasotraline 8
Normalized name: Dasotraline
DrugBank: Dasotraline (DB12305)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dasotraline 8 mg/day
Study: 10686660
Drug: Amlodipine 5
Normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5 mg orally daily for 10 days
Study: 25875257
Drug: Aerosolized vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosolized vaccine
Study: 11316646
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg NCS
Study: 11316646
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg NCS
Study: 28555052
Drug: New Zealand
Normalized name: NEW ZEALAND GREEN MUSSEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: New Zealand blackcurrant (NZBC) extract (600 mg∙day‐1 CurraNZ™)
Study: 7817618
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg lisinopril once daily
Study: 9383183
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg losartan (plus 12.5 mg hydrochlorothiazide if necessary)
Study: 31829767
Drug: Hepatitis-B virus
Normalized name: hepatitis B virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis-B virus vaccine (control)
Study: 28155569
Drug: Subconjunctival injection
Normalized name: STREPTOMYCES GRISEUS 0.05 g in 1 mL SUBCONJUNCTIVAL INJECTION, SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subconjunctival injection of demethylvancomycin
Study: 16451393
Drug: Oral deferiprone
Normalized name: Deferiprone
DrugBank: Deferiprone (DB08826)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral deferiprone (L1)
Study: 31567714
Drug: 2000 mg
Normalized name: bran 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000 mg of 5% TXA in 100 mL of isotonic saline solution
Study: 12527962
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive (OC) users
Study: 31398987
Drug: Oral sulfate
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sulfate formula (SIR) in split-dose regimen
Study: 22781352
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (Nucleoside analogue and Alpha interferon)
Study: 3318598
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (500 mg 4 times a day for 3 days)
Study: 12702905
Drug: Individualized treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized treatment (group A) - prolonged IFN therapy to maintain negative serum HBV-DNA levels for 6 months
Study: 11073745
Drug: Liposomal amphotericin
Normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal amphotericin B (5 mg/kg/d)
Study: 23059701
Drug: Behavioural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioural therapy plus usual care
Study: 10371571
Drug: PEG interleukin-2
Normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PEG interleukin-2 (2 million IU/m2 intravenous bolus every 2 months from week 2 to week 50)
Study: 18587236
Drug: 5 mg/day
Normalized name: Lyllana 0.05 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/day oral folic acid
Study: 9732167
Drug: Itraconazole 400
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole 400 mg
Study: 1580920
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of parenteral therapy (n=11 cases)
Study: 30775426
Drug: roflumilast 500
Normalized name: ROFLUMILAST 500MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: roflumilast 500 ug daily
Study: 19606690
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (conservative treatment)
Study: 23918953
Drug: Supportive-expressive group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive-expressive group therapy (SET)
Study: 21114549
Drug: karaya saponin
Normalized name: KARAYA
DrugBank: Karaya gum (DB10535)
Approvals — FDA: no, EMA: no, PMDA: no
Description: karaya saponin (various doses)
Study: 12378376
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for hypertension in microalbuminuric patients
Study: 30907187
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH) 2PN rate
Study: 29629400
Drug: Aclidinium bromide
Normalized name: Aclidinium Bromide
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Aclidinium bromide 400 µg twice daily
Study: 26974022
Drug: IT hydromorphone
Normalized name: IT-139
DrugBank: IT-139 (DB17145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IT hydromorphone at ED90 of 75 μg
Study: 26974022
Drug: IT morphine
Normalized name: IT-139
DrugBank: IT-139 (DB17145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IT morphine at ED90 of 150 μg
Study: 26974022
Drug: IT morphine
Normalized name: IT-139
DrugBank: IT-139 (DB17145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IT morphine (ED90 or higher)
Study: 7408527
Drug: Indoprofen 400
Normalized name: Neoprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Indoprofen 400 mg, 3 times a day for 1 week
Study: 19205719
Drug: Eyelid scrub
Normalized name: Ocusoft Eyelid Scrub Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eyelid scrub in addition to topical levofloxacin
Study: 2530251
Drug: Acitretin 50
Normalized name: Acitretin
DrugBank: Acitretin (DB00459)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acitretin 50 mg daily
Study: 9869503
Drug: Tedisamil dihydrochloride
Normalized name: Levocetirizine Dihydrochloride
DrugBank: Tedisamil (DB06200)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tedisamil dihydrochloride administered intravenously
Study: 2530251
Drug: Acitretin 25
Normalized name: acitretin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acitretin 25 mg daily
Study: 26176357
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of video distraction plus parental presence (group VP)
Study: 19405825
Drug: Non-submerged hollow
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-submerged hollow cylindrical and solid-screw implants with titanium plasma-sprayed surface
Study: 6373961
Drug: B subunit
Normalized name: Modified Cholera toxin B subunit
DrugBank: Modified Cholera toxin B subunit (DB18557)
Approvals — FDA: no, EMA: no, PMDA: no
Description: B subunit (high dose, 5.0 mg)
Study: 28742932
Drug: Integrated 12-Step
Normalized name: STEP 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated 12-Step facilitation (iTSF) treatment
Study: 21479749
Drug: Etodolac controlled
Normalized name: Etodolac
DrugBank: Etodolac (DB00749)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Etodolac controlled porosity osmotic pump (CPOP) tablets (F4-34)
Study: 23770005
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg golimumab
Study: 6322961
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy plus razoxane (weekly schedule: 1 gram per square meter BSA every 8 hours for two doses per week)
Study: 28771784
Drug: 6-mercaptopurine treatment
Normalized name: 6-Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6-mercaptopurine treatment intensifications
Study: 30511840
Drug: Flaxseed oil
Normalized name: Flaxseed Oil
DrugBank: Linseed oil (DB11357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed oil (n = 42, 4 capsules/day, equivalent to 2.5 g of α‐linolenic acid)
Study: 23359034
Drug: Low-dose iterative
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose iterative reconstruction (LD-IR)
Study: 28506305
Drug: Chemotherapy counseling
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy counseling module by pharmacists
Study: 12207074
Drug: Ulinastatin (UTI)
Normalized name: phenazopyridine hydrochloride Oral Tablet [UTI Relief]
DrugBank: Ulinastatin (DB12038)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ulinastatin (UTI) administered intravenously at a dose of 150,000 U every 12 h from the start of surgery until postoperative day 5
Study: 3125794
Drug: Histologic examination
Normalized name: piperonyl butoxide
DrugBank: Piperonyl butoxide (DB09350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Histologic examination after treatment with arachidonic acid
Study: 19485286
Drug: No topical
Normalized name: Altreno Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No topical cyclosporin A
Study: 6801218
Drug: Previous treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Previous treatment protocol (standardized protocol without aggressive ICP treatment)
Study: 19020533
Drug: Oral magnesium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral magnesium supplementation (MgCl(2)) 2.5 g (equivalent to 450 mg of elemental magnesium) for 4 months
Study: 16504997
Drug: Moxifloxacin 400
Normalized name: moxifloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin 400 mg orally once daily for 3 days
Study: 12898459
Drug: Testosterone (T)
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone (T) alone (50 to 75 mg, intramuscular [IM])
Study: 12898459
Drug: Combined Testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined Testosterone (T) and Growth Hormone (GH) treatment
Study: 26187277
Drug: Non-TCM treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-TCM treatment for fractures (control group).
Study: 24408162
Drug: Ponesimod 40
Normalized name: ponesimod
DrugBank: Ponesimod (DB12016)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ponesimod 40 mg (up-titration schedule)
Study: 1493666
Drug: 12,000 U
Normalized name: epoetin alfa 12,000 UNT per 0.6 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12,000 U calcium heparin s.c. every 24 h (group 2)
Study: 20827544
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (short arm cast until fracture union achieved)
Study: 29792908
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg caffeine
Study: 7668872
Drug: Chemotherapy in
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy in colon cancer cases with highly positive lymph node metastasis and positive lymphatic vessel invasion.
Study: 9794673
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of mifepristone
Study: 25572140
Drug: Daptomycin 6
Normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daptomycin 6 mg/kg IV bolus injection (10 s)
Study: 12389003
Drug: Nifedipine capsules
Normalized name: Nifedipine Capsules
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine capsules (10 mg)
Study: 19465485
Drug: High-frequency octreotide
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-frequency octreotide (30 mg/21 days)
Study: 7772487
Drug: CyA therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CyA therapy following corticosteroid treatment
Study: 2878598
Drug: Twice-daily bevantolol
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily bevantolol (200 mg)